Revisiting Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Current Practice and Novel Perspectives
Journal of Clinical Medicine · 01.09.2023 · 12 (17) · 5710
DOI: 10.3390/jcm12175710 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.09.2023. Verfasst von Andrea Ottaviani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Imaging and Clinical Sciences, "G. D'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2019 Search for Excellence Starting Grant, G.d’Annunzio University of Chieti-Pescara.
Abstract (Originalsprache)
Sarcomeric hypertrophic cardiomyopathy (HCM) is a prevalent genetic disorder characterised by left ventricular hypertrophy, myocardial disarray, and an increased risk of heart failure and sudden cardiac death. Despite advances in understanding its pathophysiology, treatment options for HCM remain limited. This narrative review aims to provide a comprehensive overview of current clinical practice and explore emerging therapeutic strategies for sarcomeric HCM, with a focus on cardiac myosin inhibitors. We first discuss the conventional management of HCM, including lifestyle modifications, pharmacological therapies, and invasive interventions, emphasizing their limitations and challenges. Next, we highlight recent advances in molecular genetics and their potential applications in refining HCM diagnosis, risk stratification, and treatment. We delve into emerging therapies, such as gene editing, RNA-based therapies, targeted small molecules, and cardiac myosin modulators like mavacamten and aficamten, which hold promise in modulating the underlying molecular mechanisms of HCM. Mavacamten and aficamten, selective modulators of cardiac myosin, have demonstrated encouraging results in clinical trials by reducing left ventricular outflow tract obstruction and improving symptoms in patients with obstructive HCM. We discuss their mechanisms of action, clinical trial outcomes, and potential implications for the future of HCM management. Furthermore, we examine the role of precision medicine in HCM management, exploring how individualised treatment strategies, including exercise prescription as part of the management plan, may optimise patient outcomes. Finally, we underscore the importance of multidisciplinary care and patient-centred approaches to address the complex needs of HCM patients. This review also aims to encourage further research and collaboration in the field of HCM, promoting the development of novel and more effective therapeutic strategies, such as cardiac myosin modulators, to hopefully improve the quality of life and outcome of patients with sarcomeric HCM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroscience, Imaging and Clinical Sciences, "G. D'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
- Barts Heart Centre, Barts Health NHS Trust, London EC1A 7BE, UK.
- Newham University Hospital, Barts Health NHS Trust, London E13 8SL, UK.
- NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London EC1A 7BE, UK.
- Inherited Cardiovascular Diseases, WellSpan Health, Lancaster, PA 17605, USA.
- Cardiac Electrophysiology, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, PA 17605, USA.
ORCID-Profile: Andrea Ottaviani, Davide Mansour, Kristian Galanti, Marco Zimarino, Francesco Pelliccia, Sabina Gallina, Fabrizio Ricci
Förderung
- 2019 Search for Excellence Starting Grant, G.d’Annunzio University of Chieti-Pescara
Zitieren
APA
Ottaviani, A., Mansour, D., Molinari, L. V., Galanti, K., Mantini, C., Khanji, M. Y., Chahal, A. A., Zimarino, M., Renda, G., Sciarra, L., Pelliccia, F., Gallina, S., & Ricci, F. (2023). Revisiting Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Current Practice and Novel Perspectives. Journal of Clinical Medicine, 12(17), 5710. https://doi.org/10.3390/jcm12175710
Vancouver
Ottaviani A, Mansour D, Molinari LV, Galanti K, Mantini C, Khanji MY, et al. Revisiting Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Current Practice and Novel Perspectives. Journal of Clinical Medicine. 2023;12(17):5710. doi:10.3390/jcm12175710
BibTeX
@article{Ottaviani2023,
author = {Ottaviani, Andrea and Mansour, Davide and Molinari, Lorenzo V and Galanti, Kristian and Mantini, Cesare and Khanji, Mohammed Y and Chahal, Anwar A and Zimarino, Marco and Renda, Giulia and Sciarra, Luigi and Pelliccia, Francesco and Gallina, Sabina and Ricci, Fabrizio},
title = {Revisiting Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Current Practice and Novel Perspectives},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {17},
pages = {5710},
doi = {10.3390/jcm12175710}
}
EUVIMED